Vertex Pharmaceuticals VRTX Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's total cost of revenue?
- Vertex Pharmaceuticals (VRTX) reported total cost of revenue of $392.8M in Q1 2026.
- How has Vertex Pharmaceuticals's total cost of revenue changed year-over-year?
- Vertex Pharmaceuticals's total cost of revenue increased by 8.2% year-over-year, from $363M to $392.8M.
- What is the long-term trend for Vertex Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's total cost of revenue has grown at a 16.2% compound annual growth rate (CAGR), from $904.2M to $1.65B.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.